Primary progressive aphasia: ReADing the clinical GRANularity.


Journal

Practical neurology
ISSN: 1474-7766
Titre abrégé: Pract Neurol
Pays: England
ID NLM: 101130961

Informations de publication

Date de publication:
Dec 2022
Historique:
accepted: 21 05 2022
pubmed: 18 6 2022
medline: 3 12 2022
entrez: 17 6 2022
Statut: ppublish

Résumé

Primary progressive aphasia remains a diagnostic challenge despite (or even because of) the increasing availability of ancillary tests and biomarkers. We present a 67-year-old man with apparently sporadic logopenic aphasia and positive Alzheimer biomarkers who was subsequently found also to have a pathogenic mutation in the progranulin gene. This was signalled by early atypical features (mild expressive agrammatism and behavioural change, rapid clinical deterioration) around the core logopenic aphasia syndrome. Each of the canonical progressive aphasia syndromes has a 'halo' of less typical variants that may herald alternative or additional pathologies. The accurate diagnosis of primary progressive aphasia depends on careful clinical analysis to direct investigations appropriately.

Identifiants

pubmed: 35710752
pii: practneurol-2022-003460
doi: 10.1136/practneurol-2022-003460
doi:

Substances chimiques

Biomarkers 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

509-514

Subventions

Organisme : Medical Research Council
ID : MR/M008525/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M023664/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T046015/1
Pays : United Kingdom
Organisme : RNID
ID : PA23
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Anthipa Chokesuwattanaskul (A)

Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Division of Neurology, Department of Internal Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Cognitive Clinical and Computational Neuroscience Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Charles R Marshall (CR)

Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.

Natasja van Harskamp (N)

Department of Neuropsychology, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Henry Houlden (H)

Department of Neurogenetics, UCL Queen Square Institute of Neurology, University College London, London, UK.

Jonathan D Rohrer (JD)

Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.

Chris Jd Hardy (CJ)

Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.

Jason D Warren (JD)

Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK jason.warren@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH